Re-engineering of EPO as the HIRMAb-EPO fusion protein fulfills both criteria for development of EPO as a biologic for brain disease: (a) penetration of the BBB, and (b) large reduction in the plasma AUC of EPO, which causes a proportionate reduction in erythropoietic action of the EPO. This evidence concerns the gene EPO and brain disorder.